Iranian Journal of Radiology

Published by: Kowsar

Time-Dependent Changes in the Magnetic Resonance Detection of Brain Metastases Using Single-Dose Gadobutrol

Bing Fan 1 , 2 , Mei-jiao Li 2 , Xiao-ying Wang 2 , * , Yu-feng Xu 2 , Fei-yu Li 2 , Lai-yun Zhang 2 , Jian Jiang 1 and Yan-yan Jiang 2
Authors Information
1 Department of Radiology, Yichang Yiling Hospital, Yichang, China
2 Department of Radiology, Peking University First Hospital, Beijing, China
Article information
  • Iranian Journal of Radiology: January 2018, 15 (1); e66054
  • Published Online: January 20, 2018
  • Article Type: Research Article
  • Received: July 10, 2016
  • Revised: September 7, 2016
  • Accepted: November 10, 2016
  • DOI: 10.5812/iranjradiol.66054

To Cite: Fan B, Li M, Wang X, Xu Y, Li F, et al. Time-Dependent Changes in the Magnetic Resonance Detection of Brain Metastases Using Single-Dose Gadobutrol, Iran J Radiol. 2018 ; 15(1):e66054. doi: 10.5812/iranjradiol.66054.

Abstract
Copyright © 2018, Iranian Journal of Radiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Mehta AI, Brufsky AM, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev. 2013;39(3):261-9. doi: 10.1016/j.ctrv.2012.05.006. [PubMed: 22727691].
  • 2. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014;20(21):5537-46. doi: 10.1158/1078-0432.CCR-13-3003. [PubMed: 24803579].
  • 3. Mastronardi L, Lunardi P, Puzzilli F, Schettini G, Lo Bianco F, Ruggeri A. The role of MRI in the surgical selection of cerebral metastases. Zentralbl Neurochir. 1999;60(3):141-5. [PubMed: 10726337].
  • 4. Dassler K, Scholle FD, Schutz G. Dynamic gadobutrol-enhanced MRI predicts early response to antivascular but not to antiproliferation therapy in a mouse xenograft model. Magn Reson Med. 2014;71(5):1826-33. doi: 10.1002/mrm.24815. [PubMed: 23754607].
  • 5. Yuh WT, Engelken JD, Muhonen MG, Mayr NA, Fisher DJ, Ehrhardt JC. Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. AJNR Am J Neuroradiol. 1992;13(1):335-45. [PubMed: 1595472].
  • 6. Yuh WT, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol. 1995;16(2):373-80. [PubMed: 7726087].
  • 7. Andreucci M, Solomon R, Tasanarong A. Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. Biomed Res Int. 2014;2014:741018. doi: 10.1155/2014/741018. [PubMed: 24895606].
  • 8. Doeblin P, Schilling R, Wagner M, Luhur R, Huppertz A, Hamm B, et al. Intraindividual comparison of T1 relaxation times after gadobutrol and Gd-DTPA administration for cardiac late enhancement imaging. Eur J Radiol. 2014;83(4):660-4. doi: 10.1016/j.ejrad.2013.12.019. [PubMed: 24433640].
  • 9. Scott LJ. Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children. Clin Drug Investig. 2013;33(4):303-14. doi: 10.1007/s40261-013-0066-0. [PubMed: 23435930].
  • 10. Gutierrez JE, Rosenberg M, Seemann J, Breuer J, Haverstock D, Agris J, et al. Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study. Magn Reson Insights. 2015;8:1-10. doi: 10.4137/MRI.S19794. [PubMed: 25922578].
  • 11. Gutierrez JE, Rosenberg M, Duhaney M, Simon JA, Brueggenwerth G, Agris JM, et al. Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast enhanced MR imaging of the central nervous system. J Magn Reson Imaging. 2015;41(3):788-96. doi: 10.1002/jmri.24583. [PubMed: 24578298].
  • 12. Anzalone N, Scarabino T, Venturi C, Cristaudo C, Tartaro A, Scotti G, et al. Cerebral neoplastic enhancing lesions, multicenter, randomized, crossover intraindividual comparison between gadobutrol, (1.0M) and gadoterate meglumine, (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. Eur J Radiol. 2013;82(1):139-45. doi: 10.1016/j.ejrad.2011.07.005. [PubMed: 21890295].
  • 13. Kramer H, Runge VM, Naul LG, Loynachan AT, Reiser MF, Wintersperger BJ. Brain MRI with single dose, (0.1 mmol/kg) Gadobutrol at 1.5 T and 3 T, comparison with 0.15 mmol/kg Gadoterate meglumine. AJR Am J Roentgenol. 2010;194(5):1337-42. doi: 10.2214/AJR.09.3427. [PubMed: 20410423].
  • 14. Maravilla KR, Smith MP, Vymazal J, Goyal M, Herman M, Baima JJ, et al. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study). AJNR Am J Neuroradiol. 2015;36(1):14-23. doi: 10.3174/ajnr.A4154. [PubMed: 25300984].
  • 15. Jeon JY, Choi JW, Roh HG, Moon WJ. Effect of imaging time in the magnetic resonance detection of intracerebral metastases using single dose gadobutrol. Korean J Radiol. 2014;15(1):145-50. doi: 10.3348/kjr.2014.15.1.145. [PubMed: 24497805].
  • 16. Morelli JN, Runge VM, Vu L, Loynachan AT, Attenberger UI. Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T. Invest Radiol. 2010;45(12):810-8. doi: 10.1097/RLI.0b013e3181f03d8a. [PubMed: 20856127].
  • 17. Katakami N, Inaba Y, Sugata S, Tsurusaki M, Itoh T, Machida T, et al. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases. Invest Radiol. 2011;46(7):411-8. doi: 10.1097/RLI.0b013e3182145a6c. [PubMed: 21467949].
  • 18. Kushnirsky M, Nguyen V, Katz JS, Steinklein J, Rosen L, Warshall C, et al. Time delayed contrast enhanced MRI improves detection of brain metastases and apparent treatment volumes. J Neurosurg. 2016;124(2):489-95. doi: 10.3171/2015.2.JNS141993. [PubMed: 26361281].
  • 19. Lin X, DeAngelis LM. Treatment of brain metastases. J Clin Oncol. 2015;33(30):3475-84. doi: 10.1200/JCO.2015.60.9503. [PubMed: 26282648].
  • 20. Seidl Z, Vymazal J, Mechl M, Goyal M, Herman M, Colosimo C, et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol. 2012;33(6):1050-8. doi: 10.3174/ajnr.A3033. [PubMed: 22383237].
  • 21. Sinha N, Ramakrishnan AG. Quality assessment in magnetic resonance images. Crit Rev Biomed Eng. 2010;38(2):127-41. [PubMed: 20932235].
  • 22. Chang JM, Moon WK, Cha JH, Jung EJ, Cho N, Kim SJ. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine. Invest Radiol. 2010;45(10):655-61. doi: 10.1097/RLI.0b013e3181ed55b4. [PubMed: 20808238].
  • 23. Morris JM, Miller GM. Increased signal in the subarachnoid space on fluid-attenuated inversion recovery imaging associated with the clearance dynamics of gadolinium chelate: a potential diagnostic pitfall. AJNR Am J Neuroradiol. 2007;28(10):1964-7. doi: 10.3174/ajnr.A0694. [PubMed: 17893215].
  • 24. Baumert BG, Rutten I, Dehing-Oberije C, Twijnstra A, Dirx MJ, Debougnoux-Huppertz RM, et al. A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys. 2006;66(1):187-94. doi: 10.1016/j.ijrobp.2006.03.050. [PubMed: 16814946].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments